Israel's BiondVax Pharmaceuticals, whose universal flu vaccine candidate has so far undergone a successful Phase II trial and is set for another next year, is thinking about a Wall Street IPO, according to Israeli newspaper Globes. Sources tell the paper the company, which has no revenue and cash reserves of 14.1 million shekels ($3.5 million), is exploring a conventional offering or listing American Depository Receipts for trading. Report